Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil. Eosinophils are evaluated in sputum samples from the airways and are commonly reported in increased levels from people with asthma. Recent work has identified that some people have symptoms of asthma but their eosinophil levels remain normal. Those with non-eosinophilic asthmatics may account for up to 50% of all asthma reported. Our study will ....Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil. Eosinophils are evaluated in sputum samples from the airways and are commonly reported in increased levels from people with asthma. Recent work has identified that some people have symptoms of asthma but their eosinophil levels remain normal. Those with non-eosinophilic asthmatics may account for up to 50% of all asthma reported. Our study will investigate the cells present in the sputum of people that have non-eosinophilic asthma. It has been speculated that neutrophils (another cell causing inflammation in the lungs) may be responsible. Neutrophils are known to cause inflammation and release many chemical mediators, which are capable of destroying lung tissue. We will focus on the neutrophil and the chemicals that cause neutrophils to move into the lungs and then destroy tissue. By comparing the levels of neutrophils and its mediators between the eosinophilic and non-eosinophilic asthma populations it may be possible to understand the mechanism behind non-eosinophilic asthma. Current asthma treatments-preventers focus essentially on controlling the inflammation caused by eosinophils. By understanding what is causing the inflammation in people without eosinophils in their sputum, we can begin to investigate and design new treatments. One possible treatment is the use of macrolide antibiotics. These medicines have been shown to be useful in reducing inflammation in other chronic inflammatory diseases. We plan to investigate the usefulness of a macrolide antibiotic (erythromycin) in reducing inflammation in non-eosinophilic asthma by a randomised-controlled trial. Armed with more information about non-eosinophilic asthma we will be able to more effectively diagnose and treat this group in the community.Read moreRead less
Dynamics And Mechanisms Of Neutrophil Migration During Tissue Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$529,577.00
Summary
Neutrophil granulocytes are central mediators of inflammatory conditions and infections. It is currently unclear how neutrophils navigate through inflamed tissues and how they detect damaged cells and/or pathogens. This proposal will use cutting-edge multi-photon microscopy to dissect the dynamics and mechanisms of neutrophil behaviour in real time in living animals. These experiments will provide a new understanding of the development of inflammatory diseases.
The Pathogenesis Of Distinct Endophenotypes Of Asthma Is Underpinned By The Collaborative Activation Of Specific PRRs.
Funder
National Health and Medical Research Council
Funding Amount
$678,754.00
Summary
Asthma is a chronic airway disease caused by inflammation. Although asthmatics can be sub-typed based on the type of inflammatory cells present in the lungs, medication specific for the treatment of these sub-types is not yet available. In this grant we will investigate the immune processes that orchestrate the development of the distinct inflammatory sub-types of asthma. This information will help us develop new therapies that will be tailored to target the appropriate type of inflammation.